#+title:      china health care
#+date:       [2025-06-08 Sun 09:28]
#+filetags:   :investment:
#+identifier: 20250608T092820

* News
** [[https://www.marketwatch.com/story/pfizer-makes-a-6-billion-run-into-a-new-cancer-drug-race-6-months-after-rival-ec832fed][Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival]]
:PROPERTIES:
:Published: [2025-05-20]
:Description: Pfizer’s licensing deal with China’s 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what Merck paid last year for its deal with China’s LaNova
:END:

** [[https://www.scmp.com/business/article/3312706/chinese-biotech-firm-akeso-tumbles-us-partner-summits-setback-cancer-drug][Chinese biotech firm Akeso tumbles on US partner Summit’s setback for cancer drug]]
:PROPERTIES:
:Published: [2025-06-02]
:Description: FDA says a ‘statistically significant’ benefit on overall survival is required to approve the ivonescimab antibody
:END:

* Drivers
** innovative drug development
oncology innovative drug
antibody-drug conjugates (ADCs)
glucagon-like peptide-1 (GLP-1)

* Risks
** regulatory
** geopolitical

* ETFs
** KURE                                                              :ATTACH:
:PROPERTIES:
:ID:       50167b78-80d4-46bf-988b-a983a3d8ab22
:END:
KraneShares MSCI All China Health Care Index ETF

* Companies
** Akeso
** 3Sbio

